CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 107,349	$ 24,039
Advance for COVAXIN supply	4,988	0
Prepaid expenses and other current assets	1,113	1,839
Total current assets	113,450	25,878
Property and equipment, net	1,052	633
Restricted cash	151	151
Other assets	1,659	714
Total assets	116,312	27,376
Current liabilities
Accounts payable	2,095	395
Accrued expenses and other current liabilities	3,962	2,941
Short-term debt, net	0	234
Operating lease obligation	172	44
Total current liabilities	6,229	3,614
Non-current liabilities
Operating lease obligation, less current portion	1,280	389
Long term debt, net	1,693	1,823
Total non-current liabilities	2,973	2,212
Total liabilities	9,202	5,826
Commitments and contingencies (Note 13)
Stockholders’ equity
Common stock; $0.01 par value; 295,000,000 and 200,000,000 shares authorized, 199,049,329 and 184,133,384 shares issued, and 198,927,829 and 184,011,884 shares outstanding at September 30, 2021 and December 31, 2020, respectively	1,990	1,841
Treasury stock, at cost, 121,500 shares at September 30, 2021 and December 31, 2020	(48)	(48)
Additional paid-in capital	222,253	93,059
Accumulated deficit	(117,086)	(73,302)
Total stockholders’ equity	107,110	21,550
Total liabilities and stockholders’ equity	116,312	27,376
Series A Preferred Stock
Stockholders’ equity
Preferred stock issued	0	0
Series B Preferred Stock
Stockholders’ equity
Preferred stock issued	$ 1	$ 0